What is the policy problem driving the populist agenda to slash pharmaceutical spending? Answer: Rising list prices and patient out-of-pocket spending.
Sam Cobb, managing director and CEO of Australian biotech AdAlta, talks about how the company has struggled to procure funding over the years and the strategies they employed to finally get listed on the Australian Securities Exchange.
Enzyvant expects its BLA for a tissue-based regenerative therapy to be reviewed and potentially approved in 2019, so solving the reimbursement issue is urgent for both the company and for patients.
The inside scoop on a program designed for women seeking board positions at biopharma companies. It’s more than just training; it’s networking assistance that is the real value.
You might know Richard Pops is one of the longest tenured CEOs in biopharma, but here are six things perhaps you didn’t know about the chairman of Alkermes.
Rachel King, CEO and cofounder of GlycoMimetics, talks about women in the biopharma industry as part of this preview of her feature story that appears in the May issue of LSL.
Richard Pops, CEO of Alkermes, discusses his philosophy of being forward looking, but shares how such an approach can also have its drawbacks.
